PDE-5 Inhibitor Prescribing Trends in US Veterans With Pulmonary Hypertension

PDE-5 Inhibitor Prescribing Trends in US Veterans With Pulmonary Hypertension

Nearly two-thirds of phosphodiesterase-5 inhibitor prescriptions for US veterans are inconsistent with pulmonary hypertension guidelines.

Claims-Based Algorithms for Pulmonary Arterial Hypertension Developed

Claims-Based Algorithms for Pulmonary Arterial Hypertension Developed

Patients with pulmonary arterial hypertension may be better identified through a claims-based algorithm that includes ICD-9-CM codes, specific pulmonary arterial hypertension medications, echocardiography, and right heart catheterization.

Comparing Prognosis of Pulmonary Arterial Hypertension in Men and Women

Comparing Prognosis of Pulmonary Arterial Hypertension in Men and Women

Women with pulmonary arterial hypertension experienced better long-term prognosis than men with PAH.

Supraventricular Arrhythmia in PAH Predicted by Right Atrium Enlargement

Supraventricular Arrhythmia in PAH Predicted by Right Atrium Enlargement

Enlargement of the right atrium is associated with an increased risk for supraventricular arrhythmias in PAH.

Varicose Veins May Increase Risk for Pulmonary Embolism

Varicose Veins May Increase Risk for Pulmonary Embolism

Varicose veins may increase the risk for pulmonary embolism and peripheral artery disease.

Idiopathic Pulmonary Arterial Hypertension and Risk for Cardiac Events

Idiopathic Pulmonary Arterial Hypertension and Risk for Cardiac Events

Peak circulatory power offers greater value than peak oxygen uptake and ventilation in predicting cardiac events in patients with idiopathic PAH.

Hypoxemia in Idiopathic Pulmonary Arterial Hypertension Linked to Increased Mortality

Hypoxemia in Idiopathic Pulmonary Arterial Hypertension Linked to Increased Mortality

Hypoxemia in individuals with idiopathic PAH is associated with increased mortality risk.

Pulmonary Embolism With Low Mortality Risk May Be Managed in Outpatient Setting

Pulmonary Embolism With Low Mortality Risk May Be Managed in Outpatient Setting

Observation in the emergency department followed by outpatient management with anticoagulation may be appropriate treatment for some patients with low-risk pulmonary embolism.

Safety and Validity of Pulmonary Embolism Rule-Out Criteria Evaluated

Safety and Validity of Pulmonary Embolism Rule-Out Criteria Evaluated

In patients at very low risk for pulmonary embolism, the pulmonary embolism rule-out criteria was noninferior to the conventional strategy of identifying thromboembolic events.

Performing Two 6MWTs in Pulmonary Hypertension Minimizes "Learning Effect"

Performing Two 6MWTs in Pulmonary Hypertension Minimizes "Learning Effect"

Patients with suspected PH should undergo two 6MWTs to improve the accuracy of exercise capacity measurements.

Prognostic Value of 6MWT in Pulmonary Arterial Hypertension

Prognostic Value of 6MWT in Pulmonary Arterial Hypertension

The 6-minute walk test had prognostic value with respect to mortality in a population of patients with pulmonary arterial hypertension.

Pulmonary Hypertension Treatments Compared for Safety, Adverse Events

Pulmonary Hypertension Treatments Compared for Safety, Adverse Events

Individuals treated with riociguat for pulmonary hypertension may have a greater risk for gastrointestinal disorders compared with tadalafil and sildenafil.

Pulmonary Arterial Hypertension: Improving Survival Rates

Pulmonary Arterial Hypertension: Improving Survival Rates

Brain natriuretic peptide levels may accurately predict 5-year survival rates in patients with pulmonary arterial hypertension.

Validity of Pulmonary Embolism Prediction Scores in Pregnant, Postpartum Women

Validity of Pulmonary Embolism Prediction Scores in Pregnant, Postpartum Women

Although the Wells and revised Geneva scores are used in the general population to predict pulmonary embolism, researchers found they were not reliable in pregnant and postpartum women.

Monitoring Pulmonary Hemodynamic Changes in CTEPH With 6-Minute Walk Test

Monitoring Pulmonary Hemodynamic Changes in CTEPH With 6-Minute Walk Test

Pulmonary hemodynamic changes in chronic thromboembolic pulmonary hypertension may be monitored via the 6-minute walk test.

Improving Prognosis in Idiopathic Pulmonary Fibrosis-Associated Pulmonary Hypertension

Improving Prognosis in Idiopathic Pulmonary Fibrosis-Associated Pulmonary Hypertension

Bosentan may benefit a subset of patients with idiopathic pulmonary fibrosis-associated pulmonary hypertension.

New Trial to Assess Dabigatran in Intermediate-Risk Pulmonary Embolism

New Trial to Assess Dabigatran in Intermediate-Risk Pulmonary Embolism

A clinical trial is underway to assess the safety and efficacy of dabigatran in intermediate-risk pulmonary embolism after completing 72 hours of heparin therapy.

REVEAL Risk Score for Long-Term Outcomes in PAH

REVEAL Risk Score for Long-Term Outcomes in PAH

The REVEAL risk score gives significant predictive value for long-term survival and changes in mortality risk in patients with PAH.

PAH: Implantable Treprostinil Delivery System Is Promising

PAH: Implantable Treprostinil Delivery System Is Promising

A fully implantable programmable intravascular delivery system using treprostinil was found to be highly stable in patients with PAH.

Pulmonary Hypertension Predicts Heart Transplant Outcomes Better Than Age

Pulmonary Hypertension Predicts Heart Transplant Outcomes Better Than Age

Pulmonary hypertension may be more important than age in predicting heart transplant outcomes.

Pulmonary Arterial Hypertension Survival May Be Linked to Kidney Function

Pulmonary Arterial Hypertension Survival May Be Linked to Kidney Function

A study evaluated whether changes in estimated glomerular filtration rate were predictive of mortality in patients with pulmonary arterial hypertension.

Pulmonary Emboli in Pediatric Patients: Clinical Predictors Identified

Pulmonary Emboli in Pediatric Patients: Clinical Predictors Identified

Prospective validation research is needed before these clinical predictors of pediatric PE can become guidelines.

Outcomes With Catheter-Directed vs Systemic Thrombolysis in Intermediate-Risk Pulmonary Emboli

Outcomes With Catheter-Directed vs Systemic Thrombolysis in Intermediate-Risk Pulmonary Emboli

A systematic review evaluated whether catheter-directed thrombolysis improved outcomes in patients with intermediate-risk pulmonary emboli.

Veno-Arterial Extracorporeal Membrane Oxygenation Effective for Massive PE

Veno-Arterial Extracorporeal Membrane Oxygenation Effective for Massive PE

The use of veno-arterial extracorporeal membrane oxygenation as bridge therapy for massive pulmonary embolism may allow clinicians to better triage patients to appropriate destination therapy.

HIV Viral Loads May Affect Echocardiographic Pulmonary Pressure

HIV Viral Loads May Affect Echocardiographic Pulmonary Pressure

Individuals who are HIV-positive may be at a higher risk for increased pulmonary pressure and mortality.

Anticoagulation Therapy Often Poorly Managed in Pulmonary Arterial Hypertension

Anticoagulation Therapy Often Poorly Managed in Pulmonary Arterial Hypertension

A study evaluated the quality of targeted anticoagulation in patients with PAH, and examined outcomes associated with poor time spent within targeted anticoagulation range.

Lung Transplantation for Pulmonary Arterial Hypertension: Overview and Bridging Therapies

Lung Transplantation for Pulmonary Arterial Hypertension: Overview and Bridging Therapies

Lung transplantation may be an option in patients with severe pulmonary arterial hypertension who do not respond well to medical therapy.

Riociguat Studied in Pediatric Patient With Pulmonary Arterial Hypertension

Riociguat Studied in Pediatric Patient With Pulmonary Arterial Hypertension

Select pediatric patients with pulmonary arterial hypertension may benefit from treatment with riociguat.

Clinical Challenge: 40-Year-Old Woman With Worsening Dyspnea on Exertion

Clinical Challenge: 40-Year-Old Woman With Worsening Dyspnea on Exertion

A 40-year-old woman presents with worsening shortness of breath after being treated with long-acting nifedipine for 2 years.

Improved Hemodynamics in CTEPH With Balloon Pulmonary Angioplasty

Improved Hemodynamics in CTEPH With Balloon Pulmonary Angioplasty

Hemodynamics may improve in patients with chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty with complication rates comparable to pulmonary endarterectomy.

Increasing 6-Minute Walking Distance in Peripheral Artery Disease

Increasing 6-Minute Walking Distance in Peripheral Artery Disease

Study results confirm the benefits of exercise vs granulocyte-macrophage colony-stimulating factor in improving 6-minute walk test in PAD.

Pulmonary Arterial Hypertension: Using Biomarkers to Assess Treatment Response

Pulmonary Arterial Hypertension: Using Biomarkers to Assess Treatment Response

Using biomarkers in pulmonary arterial hypertension may be a less invasive strategy for assessing response to treatment.

Thoracic and Pulmonary Conditions Associated With Connective Tissue Disease

Thoracic and Pulmonary Conditions Associated With Connective Tissue Disease

Pulmonary and thoracic symptoms often coincide with initial presentation of connective tissue disease.

Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: Definitions and Treatments

Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: Definitions and Treatments

Pulmonary arterial hypertension is becoming a major cause of death in patients with systemic sclerosis.

Idiopathic PAH vs Scleroderma-Associated PAH: Pulmonary Function and Hemodynamic Differences

Idiopathic PAH vs Scleroderma-Associated PAH: Pulmonary Function and Hemodynamic Differences

Results show statistically significant differences between SSc-PAH groups and iPAH groups for variables including age, sex, FVC capacity, total lung capacity, and FEV1, among others.

Impaired Cerebral Pressure-Flow Relationship in PAH

Impaired Cerebral Pressure-Flow Relationship in PAH

Patients with pulmonary arterial hypertension have reduced cerebrovascular reactivity to CO2.

Pulmonary Arterial Hypertension: Mechanisms of Exercise Intolerance

Pulmonary Arterial Hypertension: Mechanisms of Exercise Intolerance

Respiratory muscle dysfunction, iron deficiency, and skeletal muscle dysfunction have been implicated as mechanisms for exercise intolerance in pulmonary arterial hypertension.

Redesigned Inhalation Device for PAH Approved by FDA

Redesigned Inhalation Device for PAH Approved by FDA

The new device features a more ergonomic design with a single-button operation, an intuitive user interface to adjust breath counts, a rechargeable battery, and a display that guides patients through the inhalation process.

Phenotypes Associated With EIF2AK4 Mutations in PAH

Phenotypes Associated With EIF2AK4 Mutations in PAH

The frequency of eukaryotic translation initiation factor 2 alpha kinase 4 gene (EIF2AK4) mutations in patients with pulmonary arterial hypertension was investigated.

Pulmonary HTN Linked to Increased Mortality During Cardiac Catheterization

Pulmonary HTN Linked to Increased Mortality During Cardiac Catheterization

Borderline PH was linked to increased mortality after adjustment for 34 variables.

Pulmonary Edema After Prostacyclin Therapy for PAH Associated With Worse Outcomes

Pulmonary Edema After Prostacyclin Therapy for PAH Associated With Worse Outcomes

Patients who develop pulmonary edema after starting prostacyclin for pulmonary arterial hypertension have a greater risk for mortality.

PAH-Associated Congenital Heart Disease Outcomes Predicted by Pulmonary Artery Compliance

PAH-Associated Congenital Heart Disease Outcomes Predicted by Pulmonary Artery Compliance

Pulmonary vascular compliance may independently predict survival and prognosis in patients with pulmonary arterial hypertension associated with congenital heart disease.

Pulmonary Arterial Compliance Improved With Riociguat vs PDE5 Inhibitors

Pulmonary Arterial Compliance Improved With Riociguat vs PDE5 Inhibitors

Patients with pulmonary arterial hypertension experienced better improvements in pulmonary arterial compliance with riociguat compared with phosphodiesterase type 5 inhibitors.

Bronchoalveolar Lavage for Diagnosis of Idiopathic Pulmonary Fibrosis: Point/Counterpoint

Bronchoalveolar Lavage for Diagnosis of Idiopathic Pulmonary Fibrosis: Point/Counterpoint

Lung disease experts Athol Wells, MD, and Joshua Mooney, MD, MS, debate the diagnostic value of bronchoalveolar lavage in idiopathic pulmonary fibrosis.

Extent of Right Ventricular Epicardial Vascularization in Pulmonary Arterial Hypertension

Extent of Right Ventricular Epicardial Vascularization in Pulmonary Arterial Hypertension

Right ventricular epicardial vasculature is more extensive in patients with pulmonary arterial hypertension compared with individuals without disease.

No Associations Exist Between 6MWD and Maximum Oxygen Uptake in Pulmonary Arterial Hypertension

No Associations Exist Between 6MWD and Maximum Oxygen Uptake in Pulmonary Arterial Hypertension

Results indicate that further study of the relationship between the 6-minute walk distance test and functional capacity in PAH is necessary.

Association Between Pulmonary Hypertension and Hereditary Hemorrhagic Telangiectasia

Association Between Pulmonary Hypertension and Hereditary Hemorrhagic Telangiectasia

A study sought to describe the occurrence of different types of pulmonary hypertension in hereditary hemorrhagic telangiectasia.

Examining Anxiety, Depression Rates in CTEPH, PAH

Examining Anxiety, Depression Rates in CTEPH, PAH

Depression, anxiety, and reduced healthcare-related quality of life are common in patients with either pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.

Clinical Case: Patient With COPD and Worsening Dyspnea on Exertion

Clinical Case: Patient With COPD and Worsening Dyspnea on Exertion

A 65-year-old man with COPD presents with worsening exertional dyspnea.

Characteristics and Outcomes of Methamphetamine-Associated Pulmonary Arterial Hypertension

Characteristics and Outcomes of Methamphetamine-Associated Pulmonary Arterial Hypertension

Methamphetamine-associated pulmonary arterial hypertension has a higher risk for clinical worsening compared with idiopathic pulmonary arterial hypertension.

Pulmonary Veno-Occlusive Disease Affects Survival in PAH/Systemic Sclerosis

Pulmonary Veno-Occlusive Disease Affects Survival in PAH/Systemic Sclerosis

Having at least 2 features of pulmonary veno-occlusive disease demonstrated a trend toward worse survival in patients with pulmonary arterial hypertension and systemic sclerosis.

Guidelines Needed for 6-Minute Walk Test in Idiopathic Pulmonary Fibrosis

Guidelines Needed for 6-Minute Walk Test in Idiopathic Pulmonary Fibrosis

Specific guidelines should be developed for the use of the 6-minute walk test in idiopathic pulmonary fibrosis.

Pulmonary Arterial Hypertension: Future Treatment May Depend on Race and Ethnicity

Pulmonary Arterial Hypertension: Future Treatment May Depend on Race and Ethnicity

Pulmonary arterial hypertension tends to vary in presentation in patients of different races and ethnicities.

Right Ventricular Morphology Predictive of Pulmonary Hypertension Type

Right Ventricular Morphology Predictive of Pulmonary Hypertension Type

Differences in right ventricular morphology may predict the hemodynamic nature of pulmonary hypertension.

Pulmonary Endarterectomy in Chronic Thromboembolic Pulmonary Hypertension

Pulmonary Endarterectomy in Chronic Thromboembolic Pulmonary Hypertension

Pulmonary endarterectomy is an effective and durable treatment for chronic thromboembolic pulmonary hypertension.

Managing Pulmonary Hypertension in Preterm Neonates: Updates in an Emerging Field

Managing Pulmonary Hypertension in Preterm Neonates: Updates in an Emerging Field

Prenatal factors such as intrauterine growth retardation, infection, and placental inflammation can affect lung development in neonates.

No Increased Risk for VTE After Flu Vaccine in People Older Than 50

No Increased Risk for VTE After Flu Vaccine in People Older Than 50

Influenza vaccination does not increase the risk for venous thromboembolism in patients older than 50 years of age.

No Difference in Short-Term Outcome Between Saddle and Nonsaddle Pulmonary Embolism

No Difference in Short-Term Outcome Between Saddle and Nonsaddle Pulmonary Embolism

Similar short-term outcomes were seen in patients with saddle and nonsaddle pulmonary embolism.

Survival Rates in Eisenmenger Syndrome Treated With Pulmonary Vasodilator Therapy

Survival Rates in Eisenmenger Syndrome Treated With Pulmonary Vasodilator Therapy

Patients undergoing pulmonary vasodilatory therapy were more functional at initial presentation.

Poorer Right Atrial Function Predicts Worse Prognosis in Pulmonary Arterial Hypertension

Poorer Right Atrial Function Predicts Worse Prognosis in Pulmonary Arterial Hypertension

Poor outcomes in pulmonary arterial hypertension may be linked to worsening right atrial function.

Prediction of Short-, Long-Term Mortality in Elderly With Stable Acute PE

Prediction of Short-, Long-Term Mortality in Elderly With Stable Acute PE

Charleston comorbidity index is an independent predictor of mortality in patients with hemodynamically stable pulmonary embolism.

Pediatric Pulmonary Arterial Hypertension Drug Approved by FDA

Pediatric Pulmonary Arterial Hypertension Drug Approved by FDA

The first FDA-approved drug for pediatric pulmonary arterial hypertension will be available in 32 mg tablets for oral suspension.

Safety, Efficacy of Treprostinil Delivery System for PAH Examined

Safety, Efficacy of Treprostinil Delivery System for PAH Examined

Researchers were able to successfully use a fully implantable delivery system for treprostinil for adult patients with pulmonary arterial hypertension.

Using Hemodynamic Marker Ratio to Predict Outcomes in Pulmonary Hypertension

Using Hemodynamic Marker Ratio to Predict Outcomes in Pulmonary Hypertension

A retrospective analysis demonstrated that the ratio of left to right ventricular end-diastolic pressures can predict outcomes in patients with PH.

ACR Imaging Criteria for Suspected Pulmonary Hypertension

ACR Imaging Criteria for Suspected Pulmonary Hypertension

New criteria by the American College of Radiology detail appropriateness of various imaging techniques for suspected pulmonary hypertension.

Predicting Survival in IPF With CT-Measured Pulmonary Artery: Aorta Ratio

Predicting Survival in IPF With CT-Measured Pulmonary Artery: Aorta Ratio

Computed tomography-derived pulmonary artery-to-aorta ratio can predict pulmonary artery pressure and survival in patients with idiopathic pulmonary fibrosis.

Biomarkers of PAH Risk in Patients With SLE

Biomarkers of PAH Risk in Patients With SLE

Meta-analysis supports anti-RNP and anti-Sm antibodies as serological biomarkers of PAH risk in patients with SLE.

MRIs Can Predict Outcomes in Pulmonary Arterial Hypertension

MRIs Can Predict Outcomes in Pulmonary Arterial Hypertension

MRI measures can predict outcomes in pulmonary arterial hypertension.

Pulmonary Arterial Hypertension: Expert Interview

Pulmonary Arterial Hypertension: Expert Interview

Pulmonary and genetics experts James E. Loyd, MD, and Wendy Chung, MD, PhD, offer insight into the role of genetics in pulmonary arterial hypertension.

Safety and Efficacy of Combination Treatment for CTD-PAH

Safety and Efficacy of Combination Treatment for CTD-PAH

Combination therapy with ambrisentan and tadalafil may improve response in patients with connective tissue disease-associated pulmonary arterial hypertension.

Sign Up for Free e-newsletters